GSK presents new data showing promising anti-tumour activity with GSK3359609, an ICOS receptor agonist, in combination with pembrolizumab in head and neck squamous cell carcinoma (HNSCC)
Data presented at ESMO 2019 support phase II/III registrational trial with pembrolizumab in first-line recurrent/metastatic HNSCC.
